CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $7.12M, lower than 95% of all stocks globally
- PositionDebt-to-equity is 0×, lower than 95% of its Biotechnology peers (median 0.12×)
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
3.20BUSDvs all stocks (USD)
Revenue (TTM)
7.12MUSDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
0.1100xvs all stocks
52-Week Change
11.86%vs all stocks
Market Capitalization
3.20BUSDvs all stocks (USD)
Enterprise Value
2.63BUSDvs all stocks (USD)
Forward P/E
-17.43xvs Biotechnology peers
Price to Book (MRQ)
5.11xvs Biotechnology peers
Enterprise to Revenue
369.94xvs Biotechnology peers
Enterprise to EBITDA
-10.79xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
-1752.61%vs Biotechnology peers
Return on Assets (TTM)
-20.11%vs Biotechnology peers
Return on Equity (TTM)
-36.81%vs Biotechnology peers
Revenue (TTM)
7.12MUSDvs all stocks (USD)
Revenue per Share (TTM)
0.0590USDUpdated Aug 28, 2026Quarterly Revenue Growth
-80.70%vs Biotechnology peers
Gross Profit (TTM)
7.12MUSDvs all stocks (USD)
EBITDA (TTM)
-244.16MUSDvs all stocks (USD)
Net Income (TTM)
-259.50MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
-80.67%vs Biotechnology peers
Operating Cash Flow (TTM)
-143.46MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-45.36MUSDvs all stocks (USD)
Payout Ratio
0.00%vs Biotechnology peers
Revenue
22.50MUSDFY2025 · Dec 31, 2025Operating Income
-225.68MUSDvs all stocks (USD)
Pre-tax Income
-203.82MUSDFY2025 · Dec 31, 2025Income Tax Expense
0.00USDFY2025 · Dec 31, 2025Net Income
-203.82MUSDFY2025 · Dec 31, 2025EBIT
-225.68MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-219.74MUSDFY2025 · Dec 31, 2025Research & Development
141.83MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
106.35MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
27.59MUSDFY2025 · Dec 31, 2025EPS (Basic)
-1.78USDFY2025 · Dec 31, 2025EPS (Diluted)
-1.78USDFY2025 · Dec 31, 2025Basic Shares Outstanding
114.40MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
114.40MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-203.82MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-141.29MUSDFY2025 · Dec 31, 2025Free Cash Flow
-141.53MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
491.32MUSDFY2025 · Dec 31, 2025Income Tax Paid
0.00USDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-203.82MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
220.00KUSDFY2025 · Dec 31, 2025Stock-based Compensation
59.42MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
4.91MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-2.02MUSDFY2025 · Dec 31, 2025Capital Expenditures
-246.00KUSDFY2025 · Dec 31, 2025Purchase of Investments
-296.73MUSDFY2025 · Dec 31, 2025Sale of Investments
122.06MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-174.92MUSDFY2025 · Dec 31, 2025Other Financing Charges
-1.59MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
-1.59MUSDFY2025 · Dec 31, 2025Shares Outstanding
117.65MSharesUpdated Aug 28, 2026Float Shares
82.90MSharesUpdated Aug 28, 2026Shares Short
12.65MSharesUpdated Aug 28, 2026Short Ratio
11.19daysvs all stocks
Short % of Shares Outstanding
12.39%vs all stocks
% Held by Insiders
0.89%vs all stocks
% Held by Institutions
105.81%vs all stocks
Total Cash (MRQ)
633.85MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
5.30USDUpdated Aug 28, 2026Total Debt (MRQ)
82.00KUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0001xvs Biotechnology peers
Current Ratio (MRQ)
9.03xvs Biotechnology peers
Book Value per Share (MRQ)
5.37USDUpdated Aug 28, 2026Total Assets
769.28MUSDvs all stocks (USD)
Total Current Assets
675.70MUSDFY2025 · Dec 31, 2025Total Liabilities
85.85MUSDFY2025 · Dec 31, 2025Total Non-current Assets
93.58MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
66.00KUSDFY2025 · Dec 31, 2025Total Current Liabilities
85.79MUSDFY2025 · Dec 31, 2025Cash
219.39MUSDFY2025 · Dec 31, 2025Cash Equivalents
270.61MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
490.00MUSDFY2025 · Dec 31, 2025Other Short-term Investments
146.24MUSDFY2025 · Dec 31, 2025Accounts Payable
8.97MUSDFY2025 · Dec 31, 2025Short-term Debt
136.00KUSDFY2025 · Dec 31, 2025Deferred Revenue
3.99MUSDFY2025 · Dec 31, 2025Other Current Liabilities
57.27MUSDFY2025 · Dec 31, 2025Long-term Debt
66.00KUSDFY2025 · Dec 31, 2025Common Stock (Book)
14.28MUSDFY2025 · Dec 31, 2025Retained Earnings
-762.39MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
683.43MUSDvs all stocks (USD)
52-Week Low
23.05USDUpdated Aug 28, 202652-Week High
42.20USDUpdated Aug 28, 202652-Week Change
11.86%vs all stocks
Beta
0.1100xvs all stocks
50-Day MA
30.45USDUpdated Aug 28, 2026200-Day MA
33.05USDUpdated Aug 28, 2026Avg 10-Day Volume
946.44KSharesUpdated Aug 28, 2026Avg 30-Day Volume
1.09MSharesUpdated Aug 28, 2026Diluted EPS (TTM)
-2.16USDUpdated Aug 28, 2026Other Income / Expense
-5.73MUSDFY2025 · Dec 31, 20251 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company growing?
Diagnostic
High R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Heavy R&D and stock pay, with the share count growing across six years.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Debt-to-equity is 0×, lower than 95% of its Biotechnology peers (median 0.12×)Notable
Debt-to-equity: 0.00Industry median: 0.12Industry P5: 0.00Peers compared: 194
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $7.12M, lower than 95% of all stocks globallySignificant
Revenue (USD): 7,121,000Global P5: 32,166,921.735
Market cap is $3.2B, above the global median of $1.18BNotable
Market cap (USD): 3,202,400,757Global Median: 1,179,398,897.704
Companies that share the same coordination system — how they create, deliver, or capture value.
MBX Biosciences, Inc.
Tier 1ProductionApproval-Gated PipelineRule
ABL Bio Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Jilin Aodong Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Betta Pharmaceuticals Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Celldex Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
TransMedics Group Inc.
Tier 1ProductionApproval-Gated PipelineFlowRule
Disc Medicine Inc.
Tier 1ProductionApproval-Gated PipelineRule
Arcutis Biotherapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Tarsus Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Immunome Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Companies that share active interpretations — structural patterns currently present in both stocks.
Unity Software Inc.
1 interpretationHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Via Transportation, Inc.
1 interpretationHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Twist Bioscience Corporation
1 interpretationHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC